Table 2.
Incidence rate ratios (95% confidence intervals) stratified by vaccination dose intervals, and separately by SARS-CoV-2 infection intervals (*P-value ≤ 0.05, **P-value ≤ 0.01).
| ChAdOx1 vaccine | BNT162b2 vaccine | PCR-confirmed SARS-CoV-2 infection | ||||||
|---|---|---|---|---|---|---|---|---|
| Time period | Incidents | IRR (95% CI) | Incidents | IRR (95% CI) | Time period | Incidents | IRR (95% CI) | |
| Thrombocytopenia | ||||||||
| Baseline | 105 | 1.00 | 39 | 1.00 | Pre-infection | 207 | 1.00 | |
| Dose 1 | 1–14 days-pre first dose clearance | < 10 | 0.92 (0.40, 2.1) | < 10 | 0.43 (0.06, 3.18) | |||
| 0–7 days post first dose risk | 0 | – | < 10 | 2.44 (0.74, 8.05) | ||||
| 8–14 days post first dose risk | < 10 | 0.66 (0.16, 2.67) | < 10 | 0.93 (0.13, 6.84) | ||||
| 15–21 days post first dose risk | < 10 | 0.98 (0.31, 3.11) | < 10 | 0.94 (0.13, 6.90) | ||||
| 22–28 days post first dose risk | < 10 | 0.33 (0.05, 2.36) | – | – |
0–28 days post-infection |
< 10 | 1.29 (0.54, 3.07) | |
| Dose 2 | 1–14 days-pre second dose clearance | < 10 | 0.54 (0.17, 1.69) | 0 | – | |||
| 0–7 days post second dose risk | < 10 | 0.33 (0.05, 2.37) | < 10 | 0.90 (0.12, 6.56) | ||||
| 8–14 days post second dose risk | < 10 | 0.38 (0.05, 2.76) | 0 | – | ||||
| 15–21 days post second dose risk | < 10 | 1.56 (0.57, 4.26) | 0 | – | ||||
| 22–28 days post second dose risk | < 10 | 0.39 (0.05, 2.78) | < 10 | 3.15 (0.96, 10.32)* | ||||
| Dose 3 | 1–14 days-pre third dose clearance | 0 | – | < 10 | 2.45 (0.31, 19.28) | |||
| 0–7 days post third dose risk | 0 | – | – | – |
29+days post-infection |
11 | 0.24 (0.11, 0.54)** | |
| 8–14 days post third dose risk | 0 | – | – | – | ||||
| 15–21 days post third dose risk | 0 | – | – | – | ||||
| 22–28 days post third dose risk | 0 | – | – | – | ||||
| Booster | Moderna Half dose booster | BNT162b2 vaccine | ||||||
| 1–14 days-pre booster clearance | < 10 | Inf (0, Inf) | < 10 | 1.15 (0.24, 5.57) | ||||
| 0–7 days post booster risk | < 10 | Inf (0, Inf) | < 10 | 0.87 (0.10, 7.60) | ||||
| 8–14 days post booster risk | 0 | – | < 10 | 1.04 (0.12, 9.12) | ||||
| 15–21 days post booster risk | 0 | – | < 10 | 1.00 (0.11, 8.77) | ||||
| 22–28 days post booster risk | 0 | – | 0 | – | ||||
| Haemorrhage | ||||||||
| Baseline | 1927 | 1.00 | 913 | 1.00 | Pre-infection | 3999 | 1.00 | |
| Dose 1 | 1–14 days-pre first dose clearance | 78 | 0.71 (0.57, 0.89)** | 33 | 0.68 (0.48, 0.96)* | |||
| 0–7 days post first dose risk | 43 | 0.72 (0.53, 0.98)** | 24 | 0.91 (0.61, 1.37) | ||||
| 8–14 days post first dose risk | 44 | 0.86 (0.64, 1.16) | 33 | 1.47 (1.04, 2.08)* | ||||
| 15–21 days post first dose risk | 47 | 0.92 (0.69, 1.23) | 17 | 0.75 (0.47, 1.22) | ||||
| 22–28 days post first dose risk | 47 | 0.92 (0.69, 1.23) | 21 | 0.93 (0.61, 1.44) | ||||
| Dose 2 | 1–14 days-pre second dose clearance | 64 | 0.61 (0.48, 0.79)* | 29 | 0.63 (0.43, 0.91)** | |||
| 0–7 days post second dose risk | 57 | 1.01 (0.78, 1.32) | 17 | 0.68 (0.42, 1.09) |
0–28 days post-infection |
100 | 1.49 (1.15, 1.92)** | |
| 8–14 days post second dose risk | 51 | 1.05 (0.80, 1.39) | 22 | 1.02 (0.67, 1.57) | ||||
| 15–21 days post second dose risk | 50 | 1.03 (0.78, 1.37) | 17 | 0.79 (0.49, 1.28) | ||||
| 22–28 days post second dose risk | 51 | 1.05 (0.80, 1.39) | 29 | 1.35 (0.93, 1.96) | ||||
| Dose 3 | 1–14 days-pre third dose clearance | 0 | – | < 10 | 0.84 (0.33, 2.18) | |||
| 0–7 days post third dose risk | 0 | – | < 10 | – | ||||
| 8–14 days post third dose risk | 0 | – | < 10 | 1.10 (0.33, 3.60) | ||||
| 15–21 days post third dose risk | 0 | – | < 10 | 1.82 (0.70, 4.69) | ||||
| 22–28 days post third dose risk | 0 | – | < 10 | 0.70 (0.17, 2.91) |
29+days post-infection |
264 | 0.83 (0.68, 1.02) | |
| Booster | Moderna Half dose booster | BNT162b2 vaccine | ||||||
| 1–14 days-pre booster clearance | < 10 | 3.24 (0.39, 27.21) | 62 | 1.40 (1.07, 1.84)** | ||||
| 0–7 days post booster risk | < 10 | 4.64 (0.54, 39.91) | 30 | 1.13 (0.78, 1.65) | ||||
| 8–14 days post booster risk | < 10 | 1.98 (0.18, 21.91) | 22 | 0.96 (0.62, 1.48) | ||||
| 15–21 days post booster risk | < 10 | 3.33 (0.34, 32.26) | 22 | 0.95 (0.62, 1.47) | ||||
| 22–28 days post booster risk | 0 | – | 21 | 0.91 (0.58, 1.42) | ||||
| Venous thromboembolic (VTE) | ||||||||
| Baseline | 3608 | 1.00 | 1533 | 1.00 | Pre-infection | 6635 | 1.00 | |
| Dose 1 | 1–14 days-pre first dose clearance | 151 | 0.78 (0.66, 0.91)** | 54 | 0.66 (0.50, 0.87)** | |||
| 0–7 days post first dose risk | 82 | 0.78 (0.63, 0.98)** | 32 | 0.72 (0.51, 1.02) | ||||
| 8–14 days post first dose risk | 100 | 1.12 (0.91, 1.36) | 39 | 1.03(0.75, 1.41) | ||||
| 15–21 days post first dose risk | 94 | 1.05 (0.85, 1.29) | 37 | 0.97 (0.70, 1.35) | ||||
| 22–28 days post first dose risk | 71 | 0.79 (0.62, 1.00) | 31 | 0.81 (0.57, 1.16) | ||||
| Dose 2 | 1–14 days-pre second dose clearance | 96 | 0.55 (0.46, 0.67)** | 59 | 0.79 (0.61, 1.03) |
0–28 days post-infection |
525 | 5.63(4.91, 6.46)** |
| 0–7 days post second dose risk | 89 | 0.94 (0.76, 1.16) | 31 | 0.77 (0.54, 1.09) | ||||
| 8–14 days post second dose risk | 95 | 1.17 (0.96, 1.44) | 44 | 1.27 (0.94, 1.72) | ||||
| 15–21 days post second dose risk | 70 | 0.86 (0.68, 1.09) | 32 | 0.92 (0.65, 1.31) | ||||
| 22–28 days post second dose risk | 58 | 0.71 (0.55, 0.93) | 28 | 0.81 (0.56,1.17) | ||||
| Dose 3 | 1–14 days-pre third dose clearance | 0 | – | < 10 | 0.59 (0.28, 1.23) | |||
| 0–7 days post third dose risk | 0 | – | < 10 | – | ||||
| 8–14 days post third dose risk | 0 | – | < 10 | 1.12 (0.51, 2.46) | ||||
| 15–21 days post third dose risk | 0 | – | < 10 | 0.62 (0.22, 1.70) |
29+ days post-infection |
486 | 0.66 (0.57, 0.75)** | |
| 22–28 days post third dose risk | 0 | – | < 10 | 0.46 (0.14, 1.48) | ||||
| Booster | Moderna Half dose booster | BNT162b2 vaccine | ||||||
| 1–14 days-pre booster clearance | 21 | 4.60 (1.35, 15.64)** | 68 | 0.88 (0.68, 1.14) | ||||
| 0–7 days post booster risk | 11 | 3.39 (0.94, 12.20) | 31 | 0.70 (0.48, 1.01)* | ||||
| 8–14 days post booster risk | 10 | 3.62 (0.99, 13.17)* | 52 | 1.39 (1.04, 1.87)* | ||||
| 15–21 days post booster risk | < 10 | 0.67 (0.11, 3.99) | 35 | 0.92 (0.65, 1.30) | ||||
| 22–28 days post booster risk | < 10 | – | 31 | 0.81 (0.56, 1.17) | ||||
| Idiopathic thrombocytopenic purpura (ITP) | ||||||||
| Baseline | 116 | 1.00 | 78 | 1.00 | Pre-infection | 261 | 1.00 | |
| Dose 1 | 1–14 days-pre first dose clearance | < 10 | 0.61 (0.22, 1.65) | < 10 | 0.25 (0.03, 1.78) | |||
| 0–7 days post first dose risk | < 10 | 1.40 (0.57, 3.43) | < 10 | 2.80 (1.21, 6.49)* | ||||
| 8–14 days post first dose risk | < 10 | 1.31 (0.48, 3.56) | < 10 | 0.53 (0.07, 3.84) | ||||
| 15–21 days post first dose risk | < 10 | 0.98 (0.31, 3.08) | < 10 | 0.53 (0.07, 3.83) | ||||
| 22–28 days post first dose risk | < 10 | 0.97 (0.31, 3.07) | < 10 | 1.63 (0.51, 5.18) | ||||
| Dose 2 | 1–14 days-pre second dose clearance | < 10 | 0.51 (0.16, 1.62) | 0 | – | |||
| 0–7 days post second dose risk | < 10 | 1.59 (0.64, 3.93) | < 10 | 0.47 (0.07, 3.40) | ||||
| 8–14 days post second dose risk | < 10 | 0.37 (0.05, 2.64) | 0 | – |
0–28 days post-infection |
13 | 2.46 (1.14, 5.33)* | |
| 15–21 days post second dose risk | < 10 | 0.73 (0.18, 2.98) | 0 | – | ||||
| 22–28 days post second dose risk | < 10 | 1.76 (0.71, 4.36) | < 10 | 1.10 (0.27, 4.50) | ||||
| Dose 3 | 1–14 days-pre third dose clearance | 0 | – | < 10 | 0.33 (0.04, 2.84) | |||
| 0–7 days post third dose risk | 0 | – | 0 | – | ||||
| 8–14 days post third dose risk | 0 | – | 0 | – | ||||
| 15–21 days post third dose risk | 0 | – | 0 | – |
29+ days post-infection |
12 | 0.29 (0.13, 0.61)** | |
| 22–28 days post third dose risk | 0 | – | 0 | – | ||||
| Booster | Moderna Half dose booster | BNT162b2 vaccine | ||||||
| 1–14 days-pre booster clearance | < 10 | Inf (0, Inf) | < 10 | 0.77 (0.21, 2.75) | ||||
| 0–7 days post booster risk | 0 | – | < 10 | 0.89 (0.20, 4.01) | ||||
| 8–14 days post booster risk | 0 | – | < 10 | 0.50 (0.06, 3.84) | ||||
| 15–21 days post booster risk | < 10 | Inf (0, Inf) | < 10 | 1.04 (0.23, 4.69) | ||||
| 22–28 days post third dose risk | 0 | – | 0 | – | ||||
| Arterial Thrombosis | ||||||||
| Baseline | 9501 | 1.00 | 3615 | 1.00 | Pre-infection | 17,648 | 1.00 | |
| Dose 1 | 1–14 days-pre first dose clearance | 349 | 0.65 (0.58, 0.72)** | 97 | 0.55 (0.45, 0.67)** | |||
| 0–7 days post first dose risk | 242 | 0.83 (0.73, 0.95)** | 66 | 0.69 (0.54, 0.88)** | ||||
| 8–14 days post first dose risk | 255 | 1.02 (0.90, 1.16) | 55 | 0.67 (0.51, 0.87)** | ||||
| 15–21 days post first dose risk | 249 | 1.00 (0.88, 1.14) | 81 | 0.99 (0.79, 1.23) | ||||
| 22–28 days post first dose risk | 247 | 0.99 (0.87, 1.13) | 77 | 0.94 (0.75, 1.18) | ||||
| Dose 2 | 1–14 days-pre second dose clearance | 335 | 0.67 (0.60, 0.75) | 132 | 0.78 (0.65, 0.93)** | |||
| 0–7 days post second dose risk | 224 | 0.83 (0.72, 0.94)** | 77 | 0.83 (0.67, 1.05) | ||||
| 8–14 days post second dose risk | 229 | 0.99 (0.87, 1.13) | 87 | 1.10 (0.89, 1.36) |
0–28 days post-infection |
718 | 2.46 (2.22, 2.71)** | |
| 15–21 days post second dose risk | 250 | 1.08 (0.95, 1.22) | 91 | 1.15 (0.94, 1.42) | ||||
| 22–28 days post second dose risk | 264 | 1.14 (1.01, 1.29)* | 81 | 1.02 (0.82, 1.28) | ||||
| Dose 3 | 1–14 days-pre third dose clearance | < 10 | 0.35 (0.05, 2.52) | 11 | 0.68 (0.37, 1.27) | |||
| 0–7 days post third dose risk | 0 | – | 12 | 0.69 (0.36, 1.27) | ||||
| 8–14 days post third dose risk | < 10 | 0.75 (0.10, 5.39) | 10 | 1.31 (0.68, 2.51) | ||||
| 15–21 days post third dose risk | 0 | – | 14 | 1.87 (1.07, 3.28)* | ||||
| 22–28 days post third dose risk | 0 | – | < 10 | 0.91 (0.42, 1.96) | ||||
| Booster | Moderna Half dose booster | BNT162b2 vaccine |
29+ days post-infection |
983 | 0.44 (0.40, 0.48)** | |||
| 1–14 days-pre booster clearance | 48 | 6.77 (2.67, 17.17)** | 229 | 0.84 (0.73, 0.97)* | ||||
| 0–7 days post booster risk | 27 | 5.21 (2.00, 13.56)** | 148 | 0.96 (0.81, 1.14) | ||||
| 8–14 days post booster risk | 15 | 3.14 (1.14, 8.64)* | 176 | 1.34 (1.15, 1.58)** | ||||
| 15–21 days post booster risk | 12 | 2.49 (0.88, 7.07) | 128 | 0.96 (0.80, 1.16) | ||||
| 22–28 days post third dose risk | < 10 | – | 125 | 0.94 (0.78, 1.14) | ||||
| Ischaemic stroke | ||||||||
| Baseline | 2410 | 1.00 | 876 | 1.00 | Pre-infection | 3799 | 1.00 | |
| Dose 1 | 1–14 days-pre first dose clearance | 78 | 0.56 (0.45, 0.71)** | 16 | 0.36 (0.22, 0.59)** | |||
| 0–7 days post first dose risk | 56 | 0.75 (0.57, 0.97)* | 18 | 0.75 (0.47, 1.2) | ||||
| 8–14 days post first dose risk | 73 | 1.14 (0.9, 1.44) | 13 | 0.63 (0.36, 1.09) | ||||
| 15–21 days post first dose risk | 48 | 0.75 (0.56, 0.99)* | 26 | 1.27 (0.86, 1.88) | ||||
| 22–28 days post first dose risk | 64 | 1 (0.78, 1.28) | 16 | 0.78 (0.48, 1.28) | ||||
| Dose 2 | 1–14 days-pre second dose clearance | 68 | 0.54 (0.43, 0.69)** | 17 | 0.4 (0.25, 0.64)** | |||
| 0–7 days post second dose risk | 53 | 0.78 (0.59, 1.02) | 20 | 0.86 (0.55, 1.35) | ||||
| 8–14 days post second dose risk | 52 | 0.89 (0.68, 1.18) | 23 | 1.16 (0.77, 1.76) | 0–28 days post-infection | 143 | 1.41 (1.15, 1.72)** | |
| 15–21 days post second dose risk | 67 | 1.15 (0.9, 1.47) | 28 | 1.41 (0.97, 2.06) | ||||
| 22–28 days post second dose risk | 60 | 1.03 (0.8, 1.33) | 25 | 1.26 (0.85, 1.88) | ||||
| Dose 3 | 1–14 days-pre third dose clearance | < 10 | 3.52 (0.73, 16.95) | < 5 | 1.14 (0.36, 3.60) | |||
| 0–7 days post third dose risk | < 10 | 2.94 (0.59, 14.68) | < 5 | – | ||||
| 8–14 days post third dose risk | < 10 | 2.15 (0.39, 11.75) | < 5 | 1.09 (0.23, 5.04) | ||||
| 15–21 days post third dose risk | < 10 | 1.05 (0.15, 7.46) | < 5 | 0.95 (0.20, 4.44) | ||||
| 22–28 days post third dose risk | < 10 | – | < 5 | 0.48 (0.06, 3.79) |
29+ days post-infection |
273 | 0.34 (0.29, 0.40)** | |
| Booster | Moderna Half dose booster | BNT162b2 vaccine | ||||||
| 1–14 days-pre booster clearance | 0 | – | 44 | 0.75 (0.55, 1.04) | ||||
| 0–7 days post booster risk | 0 | – | 38 | 1.15 (0.82, 1.62) | ||||
| 8–14 days post booster risk | 0 | – | 24 | 0.83 (0.55, 1.27) | ||||
| 15–21 days post booster risk | 0 | – | 30 | 1.05 (0.72, 1.54) | ||||
| 22–28 days post third dose risk | 0 | – | 31 | 1.09 (0.75, 1.58) | ||||
| Myocardial infarction | ||||||||
| Baseline | 1950 | 1.00 | 760 | 1.00 | Pre-infection | 3799 | 1.00 | |
| Dose 1 | 1–14 days-pre first dose clearance | 69 | 0.63 (0.49, 0.8)** | 16 | 0.4 (0.25, 0.66)** | |||
| 0–7 days post first dose risk | 38 | 0.63 (0.46, 0.87)** | 25 | 1.18 (0.79, 1.75) | ||||
| 8–14 days post first dose risk | 48 | 0.94 (0.7, 1.25) | 18 | 0.98 (0.62, 1.57) | ||||
| 15–21 days post first dose risk | 58 | 1.14 (0.87, 1.47) | 17 | 0.93 (0.57, 1.51) | ||||
| 22–28 days post first dose risk | 40 | 0.78 (0.57, 1.06) | 17 | 0.93 (0.58, 1.51) | ||||
| Dose 2 | 1–14 days-pre second dose clearance | 57 | 0.57 (0.43, 0.74)** | 13 | 0.35 (0.20, 0.60)** | |||
| 0–7 days post second dose risk | 48 | 0.88 (0.66, 1.17) | 21 | 1.03 (0.67, 1.59) | ||||
| 8–14 days post second dose risk | 50 | 1.07 (0.81, 1.41) | 15 | 0.86 (0.51, 1.43) |
0–28 days post-infection |
123 | 1.94 (1.54, 2.46)** | |
| 15–21 days post second dose risk | 54 | 1.15 (0.88, 1.51) | 20 | 1.14 (0.73, 1.79) | ||||
| 22–28 days post second dose risk | 54 | 1.15 (0.88, 1.51) | 22 | 1.26 (0.83, 1.93) | ||||
| Dose 3 | 1–14 days-pre third dose clearance | 0 | – | < 5 | 0.25 (0.03, 2.02) | |||
| 0–7 days post third dose risk | 0 | – | < 5 | Inf (0, Inf) | ||||
| 8–14 days post third dose risk | 0 | – | 0 | – | ||||
| 15–21 days post third dose risk | 0 | – | 0 | – |
29+ days post-infection |
180 | 0.38 (0.31, 0.47)** | |
| 22–28 days post third dose risk | 0 | – | < 5 | 2.08 (0.62, 6.97) | ||||
| Booster | Moderna Half dose booster | BNT162b2 vaccine | ||||||
| 1–14 days-pre booster clearance | < 10 | 2.85 (0.56, 14.57) | 31 | 0.62 (0.43, 0.91)** | ||||
| 0–7 days post booster risk | – | – | 33 | 1.18 (0.82, 1.71) | ||||
| 8–14 days post booster risk | < 10 | 2.21 (0.4, 12.14) | 31 | 1.28 (0.88, 1.87) | ||||
| 15–21 days post booster risk | < 10 | 0.5 (0.05, 5.58) | 23 | 0.96 (0.62, 1.47) | ||||
| 22–28 days post third dose risk | < 10 | Inf (0, Inf) | 23 | 0.95 (0.61, 1.46) | ||||